Scimeca, M.; Montanaro, M.; Bonfiglio, R.; Anemona, L.; Agrò, E.F.; Asimakopoulos, A.D.; Bei, R.; Manzari, V.; Urbano, N.; Giacobbi, E.;
et al. The ETS Homologous Factor (EHF) Represents a Useful Immunohistochemical Marker for Predicting Prostate Cancer Metastasis. Diagnostics 2022, 12, 800.
https://doi.org/10.3390/diagnostics12040800
AMA Style
Scimeca M, Montanaro M, Bonfiglio R, Anemona L, Agrò EF, Asimakopoulos AD, Bei R, Manzari V, Urbano N, Giacobbi E,
et al. The ETS Homologous Factor (EHF) Represents a Useful Immunohistochemical Marker for Predicting Prostate Cancer Metastasis. Diagnostics. 2022; 12(4):800.
https://doi.org/10.3390/diagnostics12040800
Chicago/Turabian Style
Scimeca, Manuel, Manuela Montanaro, Rita Bonfiglio, Lucia Anemona, Enrico Finazzi Agrò, Anastasios D. Asimakopoulos, Roberto Bei, Vittorio Manzari, Nicoletta Urbano, Erica Giacobbi,
and et al. 2022. "The ETS Homologous Factor (EHF) Represents a Useful Immunohistochemical Marker for Predicting Prostate Cancer Metastasis" Diagnostics 12, no. 4: 800.
https://doi.org/10.3390/diagnostics12040800
APA Style
Scimeca, M., Montanaro, M., Bonfiglio, R., Anemona, L., Agrò, E. F., Asimakopoulos, A. D., Bei, R., Manzari, V., Urbano, N., Giacobbi, E., Servadei, F., Bonanno, E., Schillaci, O., & Mauriello, A.
(2022). The ETS Homologous Factor (EHF) Represents a Useful Immunohistochemical Marker for Predicting Prostate Cancer Metastasis. Diagnostics, 12(4), 800.
https://doi.org/10.3390/diagnostics12040800
